1. Home
  2. AZN
  3. AZN News

Latest AstraZeneca PLC (AZN) News on June 2, 2025

How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
AZN

Investor's Business Daily

2 hours ago

How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
AZN

Business Wire

2 hours ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

AZN

MT Newswires

3 hours ago

AstraZeneca Says DATROWAY Shows Promising Results in Combination Trials for Lung Cancer

AZN

MT Newswires

3 hours ago

AstraZeneca, Daiichi Sankyo's Gastric Cancer Phase 3 Trial Shows 'Statistically Significant' Improvement in Overall Survival

AZN

MT Newswires

6 hours ago

AstraZeneca Says Imfinzi Combo Boosts Event-Free Survival in Gastric Cancer Trial

AZN

MT Newswires

6 hours ago

AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial

Enhertu potential broadens as new data point to frontline breast cancer role
AZN

BioPharma Dive

6 hours ago

Enhertu potential broadens as new data point to frontline breast cancer role

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
AZN

Business Wire

a day ago

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
AZN

Reuters

a day ago

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
AZN

Business Wire

a day ago

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

AstraZeneca drug could help keep a common breast cancer at bay
AZN

BioPharma Dive

a day ago

AstraZeneca drug could help keep a common breast cancer at bay

At ASCO, Enhertu cements growing role in stomach cancer care
AZN

BioPharma Dive

2 days ago

At ASCO, Enhertu cements growing role in stomach cancer care

AZN

Morningstar Research

3 days ago

Analyst Report: AstraZeneca PLC

Danaher Partners With AstraZeneca to Support Precision Medicine
AZN

Zacks

3 days ago

Danaher Partners With AstraZeneca to Support Precision Medicine

Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
AZN

Zacks

3 days ago

Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?

Danaher and AstraZeneca to develop diagnostic tools and tests
AZN

Medical Device Network

3 days ago

Danaher and AstraZeneca to develop diagnostic tools and tests

Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests
AZN

Insider Monkey

3 days ago

Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests

AZN

MT Newswires

4 days ago

Danaher, AstraZeneca Collaborate on Precision Medicine

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
AZN

PR Newswire

4 days ago

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
AZN

Zacks

5 days ago

Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?

AstraZeneca (LSE:AZN) Gains EU Recommendation For Imfinzi in Bladder Cancer Treatment
AZN

Simply Wall St.

6 days ago

AstraZeneca (LSE:AZN) Gains EU Recommendation For Imfinzi in Bladder Cancer Treatment

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer
AZN

Zacks

6 days ago

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
AZN

Zacks

7 days ago

Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer

AZN

MT Newswires

10 days ago

European Equities Close Sharply Lower in Friday Trading; German Q1 GDP Expands 0.4% Sequentially

AZN

MT Newswires

10 days ago

Astrazeneca's Imfinzi Gets Expanded EU Committee Recommendation to Include Muscle Invasive Bladder Cancer

Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
AZN

Pharmaceutical Technology

10 days ago

Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection

FDA to mandate trials for COVID boosters for healthy kids and adults
AZN

TipRanks

12 days ago

FDA to mandate trials for COVID boosters for healthy kids and adults

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
AZN

Zacks

12 days ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust
AZN

Zacks

12 days ago

The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust

AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AZN

Zacks

12 days ago

AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
AZN

Business Wire

12 days ago

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

3 Promising Growth Stocks You Can Buy for Less Than $100
AZN

Motley Fool

13 days ago

3 Promising Growth Stocks You Can Buy for Less Than $100

Top Research Reports for Visa, AstraZeneca & Shell
AZN

Zacks

13 days ago

Top Research Reports for Visa, AstraZeneca & Shell

AstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma Risks
AZN

Simply Wall St.

13 days ago

AstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma Risks

AstraZeneca says Airsupra reduced severe asthma risk by 47%
AZN

TipRanks

13 days ago

AstraZeneca says Airsupra reduced severe asthma risk by 47%

AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%
AZN

Insider Monkey

14 days ago

AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%

AZN

MT Newswires

14 days ago

Astrazeneca's Asthma Therapy Shows Improvement Across Primary and Secondary Endpoints in Late-Stage Trial

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
AZN

Business Wire

14 days ago

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
AZN

Zacks

18 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?
AZN

Insider Monkey

20 days ago

Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
AZN

Business Wire

20 days ago

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

AZN

Pharmaceutical Technology

20 days ago

MHRA approves AstraZeneca’s Trixeo Aerosphere inhaler for COPD

AZN

Morningstar Research

21 days ago

Analyst Report: AstraZeneca PLC

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower
AZN

Bloomberg

21 days ago

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
AZN

The Wall Street Journal

21 days ago

Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
AZN

The Wall Street Journal

21 days ago

Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial
AZN

Clinical Trials Arena

21 days ago

AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial

AZN

MT Newswires

21 days ago

Pharma Shares Fall Pre-Bell Following Plan by Trump to Reduce US Prescription Drug Prices

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices
AZN

Bloomberg

21 days ago

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer
AZN

Simply Wall St.

23 days ago

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
AZN

Zacks

24 days ago

How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
AZN

Zacks

24 days ago

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

AZN

MT Newswires

24 days ago

AstraZeneca's Imfinzi Combination Therapy Boosts Disease-Free Survival in Bladder Cancer Trial

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
AZN

Business Wire

24 days ago

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
AZN

Clinical Trials Arena

25 days ago

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment
AZN

Simply Wall St.

a month ago

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

AZN

MT Newswires

a month ago

AstraZeneca Says Enhertu Followed by THP Improved Pathologic Complete Response Rate in Breast Cancer Study

AZN

Thomson Reuters StreetEvents

a month ago

Q1 2025 Arcus Biosciences Inc Earnings Call

Expediting parallel drug approval pathways is challenging, but rewarding
AZN

Pharmaceutical Technology

a month ago

Expediting parallel drug approval pathways is challenging, but rewarding

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
AZN

Business Wire

a month ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

EC approves AstraZeneca’s Calquence combo to treat MCL
AZN

Pharmaceutical Technology

a month ago

EC approves AstraZeneca’s Calquence combo to treat MCL

AZN

GuruFocus.com

a month ago

Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

AZN or ARGX: Which Is the Better Value Stock Right Now?
AZN

Zacks

a month ago

AZN or ARGX: Which Is the Better Value Stock Right Now?

AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye
AZN

Simply Wall St.

a month ago

AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
AZN

Zacks

a month ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
AZN

Simply Wall St.

a month ago

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma
AZN

Simply Wall St.

a month ago

AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma

Here's what top C-suites are saying about tariffs
AZN

Yahoo Finance Video

a month ago

Here's what top C-suites are saying about tariffs

AZN

MT Newswires

a month ago

European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
AZN

Benzinga

a month ago

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
AZN

Motley Fool

a month ago

Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.

Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth
AZN

Zacks

a month ago

Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth

AZN

MT Newswires

a month ago

Astrazeneca Asthma Treatment Study Meets Primary Endpoints

AstraZeneca’s triple-combo triumphs in two Phase III asthma trials
AZN

Clinical Trials Arena

a month ago

AstraZeneca’s triple-combo triumphs in two Phase III asthma trials

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
AZN

Business Wire

a month ago

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat
AZN

Yahoo Finance

a month ago

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
AZN

Zacks

a month ago

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

AstraZeneca quietly exits neuroscience
AZN

BioPharma Dive

a month ago

AstraZeneca quietly exits neuroscience

3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value
AZN

Simply Wall St.

a month ago

3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value

Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC
AZN

Clinical Trials Arena

a month ago

Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC

AstraZeneca’s Truqap fails in another Phase III trial
AZN

Pharmaceutical Technology

a month ago

AstraZeneca’s Truqap fails in another Phase III trial

AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
AZN

GuruFocus.com

a month ago

AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss
AZN

Investor's Business Daily

a month ago

AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss

AZN

Morningstar Research

a month ago

Analyst Report: AstraZeneca PLC

AZN

MT Newswires

a month ago

Sector Update: Health Care Stocks Gain Late Afternoon

AstraZeneca CEO calls for increased European investment in pharma
AZN

Pharmaceutical Technology

a month ago

AstraZeneca CEO calls for increased European investment in pharma

AZN

MT Newswires

a month ago

Sector Update: Health Care Stocks Higher Tuesday Afternoon

AZN

MT Newswires

a month ago

Astrazeneca Does not Expect Material Long-Term Impact From US Tariffs, CEO Says

AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops
AZN

Investor's Business Daily

a month ago

AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy
AZN

GlobeNewswire

a month ago

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China
AZN

The Wall Street Journal

a month ago

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors
AZN

Reuters

a month ago

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors

AZN

Associated Press Finance

a month ago

Astrazeneca: Q1 Earnings Snapshot

AZN

MT Newswires

a month ago

AstraZeneca's Q1 Core Earnings, Revenue Rise; Reaffirms 2025 Guidance

AstraZeneca's Q1 2025 Financial Results
AZN

Business Wire

a month ago

AstraZeneca's Q1 2025 Financial Results

Coca-Cola earnings, JOLTS, Consumer Confidence: What to Watch
AZN

Yahoo Finance Video

a month ago

Coca-Cola earnings, JOLTS, Consumer Confidence: What to Watch

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
AZN

Zacks

a month ago

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS

Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
AZN

Zacks

a month ago

Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?

Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
AZN

Zacks

a month ago

Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics

AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
AZN

Pharmaceutical Technology

a month ago

AstraZeneca enters $200m AI cancer pact with Tempus and Pathos

Share on Social Networks: